Novo Nordisk A/S $NVO Shares Bought by Rhumbline Advisers

Rhumbline Advisers boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 10.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 63,539 shares of the company's stock after buying an additional 5,898 shares during the period. Rhumbline Advisers' holdings in Novo Nordisk A/S were worth $4,412,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Revolve Wealth Partners LLC grew its stake in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after buying an additional 200 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Novo Nordisk A/S by 3.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,080 shares of the company's stock worth $8,179,000 after acquiring an additional 2,920 shares in the last quarter. Silvercrest Asset Management Group LLC grew its holdings in shares of Novo Nordisk A/S by 3.1% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 127,998 shares of the company's stock worth $11,010,000 after purchasing an additional 3,881 shares during the last quarter. Toronto Dominion Bank boosted its holdings in Novo Nordisk A/S by 494.1% in the fourth quarter. Toronto Dominion Bank now owns 88,295 shares of the company's stock valued at $7,595,000 after acquiring an additional 73,432 shares during the last quarter. Finally, Strive Asset Management LLC bought a new position in Novo Nordisk A/S in the fourth quarter valued at about $228,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently commented on NVO. Dbs Bank raised Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, August 22nd. Hsbc Global Res cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 31st. HSBC cut Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective on the stock. in a research report on Thursday, July 31st. BNP Paribas Exane upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price target on the stock in a research report on Wednesday, August 13th. Finally, BNP Paribas raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research note on Wednesday, August 13th. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Hold" and an average target price of $81.00.

Novo Nordisk A/S Trading Up 1.2%

NYSE NVO opened at $54.94 on Monday. The company has a market cap of $245.31 billion, a price-to-earnings ratio of 15.09, a P/E/G ratio of 2.08 and a beta of 0.66. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $138.22. The business has a 50 day moving average price of $57.96 and a 200-day moving average price of $66.17. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio is currently 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.